Shamburg News · 8-K filed Nov 16, 2026, 8:15 AM EST
CG Oncology Reports PIVOT-006 Phase 3 Topline Results in Intermediate-Risk NMIBC
CGON · CG Oncology, Inc.
- Other event
- Reg FD disclosure
- Materiality: high
On November 16, 2026, CG Oncology announced positive topline results from its Phase 3 PIVOT-006 trial of adjuvant intravesical cretostimogene in intermediate-risk and high-grade Ta NMIBC, achieving its primary endpoint with a 68% reduction in recurrence risk and a hazard ratio of 0.32 (95% CI: 0.23, 0.45). The company reported no Grade 3 or higher TRAEs and no treatment-related discontinuations. It also updated BLA timing: the BCG-unresponsive submission, now broadened to include high-grade papillary-only disease, is expected to be completed in March 2027, and a second BLA in intermediate-risk and high-grade Ta NMIBC is planned for the second quarter of 2027.
Source: SEC EDGAR, Form 8-K, Items 7.01, 8.01, 9.01, accession 0001193125-26-462199.
Written from the filing by Shamburg Markets. Figures are as reported by the company.